Also known as: Sprycel
Dasatinib is an oral targeted tyrosine kinase inhibitor used for Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphoblastic leukemia. It is marketed as Sprycel and has approvals in the U.S. and EU since 2006. It is a prescription oncology medicine.
A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.
Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.
New AI-powered platforms enable same-day cancer treatment decisions and streamline clinical trial matching. University of Utah's μPharma chip predicts drug responses in under four hours, while City of Hope's HopeLLM system matches patients to trials across its national network.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
New CAR T-cell approaches targeting BCMA and CD19 simultaneously show encouraging early results, while researchers develop control strategies for CAR-T therapies including antibody-drug conjugates.
Recent studies demonstrate significant advances in engineered immune cell therapies, including enhanced CAR-T cells for solid tumors through NR2F6 deletion and mass production of CAR-NK cells from cord blood stem cells capable of generating millions of tumor-killing cells.
Recent advances in chimeric antigen receptor cell therapies highlight improved designs for CAR-T and CAR-NK treatments, with new strategies addressing efficacy and safety challenges in both hematologic and solid tumors.
Bristol Myers Squibb faces a steep patent cliff with key drugs losing protection between 2027-2029, but newer products like Cobenfy show promise. The stock trades at less than 10 times earnings with a 4.2% dividend yield.
West Virginia University Cancer Institute has dosed the first patient in a phase 1/2 trial evaluating subcutaneous blinatumomab for CD19-positive mixed-phenotype acute leukemia, a rare disease with no FDA-approved therapies. The first patient achieved complete remission after one cycle.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07493408 |
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML |
NOT_YET_RECRUITING | PHASE2 |
| NCT07342491 |
Dasatinib for HIV-1 Reservoir Reduction |
NOT_YET_RECRUITING | PHASE1 |
| NCT07269470 |
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase |
NOT_YET_RECRUITING | PHASE2 |
| NCT07144293 |
Improving Physical Ability and Cellular Senescence Elimination in HIV |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07025226 |
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease |
RECRUITING | EARLY_PHASE1 |
| NCT07000734 |
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study |
COMPLETED | PHASE2 |
| NCT06940297 |
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma |
RECRUITING | PHASE2 |
| NCT06855810 |
Newly-diagnosed Pediatric T-cell ALL Protocol |
RECRUITING | PHASE2/PHASE3 |
| NCT06645886 |
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06533748 |
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma |
RECRUITING | PHASE2 |
